Furthermore, the studies focused on targeting more than 1 antigen, such as CD19 with either CD20 or CD22, are ongoing [53,54] and might change the paradigm of the r/r ALL treatment. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.